Results 51 to 60 of about 2,826,854 (328)
ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. [PDF]
, 2014 BackgroundDolutegravir (DTG), a once-daily, human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, was evaluated for distribution and antiviral activity in cerebrospinal fluid (CSF).MethodsING116070 is an ongoing, single-arm, open-label ...
Chen, Shuguang +8 more
core +3 more sources
Lipid abnormality correction by integrase inhibitor among children taking ARt
Журнал инфектологии, 2019 Goal. To estimate a possibility of correction laboratory abnormalities (increased level of cholesterol and/or triglycerides at blood of HIV-positive children) by switch the boosted PI on HIV integrase inhibitor (Raltegravir). Methods.
A. V. Samarina +5 more
doaj +1 more source
Nucleolar Localization of HIV-1 Rev Is Required, Yet Insufficient for Production of Infectious Viral Particles. [PDF]
, 2018 Combination antiretroviral therapy fails in complete suppression of HIV-1 due to drug resistance and persistent latency. Novel therapeutic intervention requires knowledge of intracellular pathways responsible for viral replication, specifically those ...
Arizala, Jerlisa Ann C +5 more
core +1 more source
Authentic HIV-1 Integrase Inhibitors [PDF]
Future Medicinal Chemistry, 2010 HIV-1 integrase (IN) is indispensable for HIV-1 replication and has become a validated target for developing anti-AIDS agents. In two decades of development of IN inhibition-based anti-HIV therapeutics, a significant number of compounds were identified as IN inhibitors, but only some of them showed antiviral activity.
Terrence R. Burke +4 more
openaire +3 more sources
Dolutegravir-based regimen maintains virological success in a patient with archived mutations to integrase inhibitors [PDF]
, 2017 no abstract ...
Falasca, Francesca +3 more
core +1 more source
Biomolecules, 2020 The search for compounds that can inhibit the interaction of certain viral proteins with their cellular partners is a promising trend in the development of antiviral drugs.
Simon Galkin +4 more
doaj +1 more source
Antimicrobial Agents and Chemotherapy, 2019 We compared the activity of the integrase inhibitor bictegravir against HIV-1 and HIV-2 using a culture-based, single-cycle assay. Values of 50% effective concentrations ranged from 1.2 to 2.5 nM for 9 HIV-1 isolates and 1.4 to 5.6 nM for 15 HIV-2 ...
Robert A. Smith +7 more
semanticscholar +1 more source
Pyrone-based inhibitors of metalloproteinase types 2 and 3 may work as conformation-selective inhibitors. [PDF]
, 2011 Matrix metalloproteinases are zinc-containing enzymes capable of degrading all components of the extracellular matrix. Owing to their role in human disease, matrix metalloproteinase have been the subject of extensive study.
de Oliveira, César AF +2 more
core +1 more source
Viruses, 2023 After a decade of dolutegravir (DTG) use in various antiretroviral therapy combinations and in diverse populations globally, it is critical to identify HIV strains with reduced drug susceptibility and monitor emergent resistance in people living with HIV
Cassidy Henegar +7 more
doaj +1 more source
Elvitegravir: A New HIV Integrase Inhibitor [PDF]
Antiviral Chemistry and Chemotherapy, 2009 Integration is a distinctive and essential process in the HIV infection cycle and thus represents an attractive antiviral drug target. Integrase inhibitors combined with other classes of drug might contribute to long-lasting suppression of HIV type-1 (HIV-1) replication for many patients.
Kazuya Shimura +2 more
openaire +3 more sources